Precision BioSciences Inc. Beats Earnings and Revenue Forecasts - DTIL Surges

Core Insights - Precision BioSciences Inc. reported adjusted earnings of $0.36 per share, significantly surpassing the Zacks Consensus Estimate of a -$0.21 loss per share, marking an earnings surprise of +271.43% and a notable improvement from the adjusted loss of $3.2 per share in the same quarter last year [1][2] - The company's revenue for the quarter ended December 31, 2025, was $34.2 million, exceeding the Zacks Consensus Estimate by 178.08%, and reflecting a dramatic increase from $0.6 million in the prior-year quarter, primarily driven by collaboration-related payments [2][3] - Precision BioSciences operates in the Zacks Medical - Biomedical and Genetics industry and announced its Q4 and fiscal year 2025 financial results on March 12, 2026 [3] Market Performance - On March 13, 2026, Jefferies set a price target of $19 for DTIL, lowered from a prior $21, while maintaining a positive outlook, indicating a potential upside of approximately 235% from the stock's trading price of $5.67 [4] - The company's market capitalization is approximately $130 million, with a trading volume of 277,693 shares on March 13, 2026, and the stock has ranged from a low of $3.53 to a high of $8.82 over the past year [5] Clinical Developments - Precision BioSciences has made significant clinical progress with its PBGENE-HBV program for chronic hepatitis B, presenting late-breaking Phase 1 data from the ELIMINATE-B trial, demonstrating safety, tolerability, and antiviral activity [6] - The CEO highlighted these advancements as positioning the company for continued success in 2026 and beyond, supported by an extended cash runway through 2028 following the strong quarterly results [7]